NR1H4 and obesity due to melanocortin 4 receptor deficiency: Consequently, FXR represents a promising target for the treatment of metabolic disorders, showing beneficial effects in different diseases such as cholestasis, nonalcoholic steatohepatitis (NASH), obesity, and liver fibrosis.